SCHEMBL29566844

SCHEMBL29566844

CC(C)Cc1ccccc1-c1nc(NS(=O)(=O)c2cnn(C)c2)nc(Oc2ccc(C3CCN(C)CC3)cc2)c1C(F)(F)F

nearest known ligand 0.34

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ PTK2 Q05397 8/20 0.34
▸ HTR1A P08908 5/20 0.33
▸ HTR7 P34969 5/20 0.33
▸ KCNH2 Q12809 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ FLT4 P35916 3/20 0.32
▸ KDR P35968 2/20 0.32
▸ JAK2 O60674 3/20 0.32
▸ JAK3 P52333 3/20 0.32
▸ NMT1 P30419 1/20 0.32
▸ MAP4K1 Q92918 1/20 0.32
▸ SLC8A1 P32418 1/20 0.31
▸ BRAF P15056 1/20 0.31
▸ SCN9A Q15858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310411 1.00 PTK2 (0.34) PTK2HTR1AHTR7KCNH2DRD2
SCHEMBL29568105 0.93 PTK2 (0.34) PTK2HTR1AHTR7DRD2HTR6
SCHEMBL24309837 0.93 PTK2 (0.34) PTK2HTR1AHTR7DRD2HTR6
SCHEMBL26808560 0.92 PTK2 (0.34) PTK2HTR1AHTR7FLT4KDR
SCHEMBL26808620 0.91 PTK2 (0.35) PTK2HTR1AHTR7FLT4KDR
SCHEMBL24309960 0.91 PTK2 (0.32) PTK2HTR1AHTR7KCNH2DRD2
SCHEMBL24310415 0.90 HTR1A (0.39) PTK2HTR1AHTR7DRD2HTR6
SCHEMBL29566359 0.90 HTR1A (0.39) PTK2HTR1AHTR7DRD2HTR6
SCHEMBL26808552 0.90 PTK2 (0.33) PTK2HTR1AHTR7FLT4KDR
SCHEMBL29566951 0.90 HTR1A (0.34) PTK2HTR1AHTR7KCNH2DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback